Bio-Rad Laboratories, Inc. (BIO) Stock Price & Analysis
Bio-Rad Laboratories, Inc. (BIO) closed at USD 363.5 on Thursday, October 22, 2026, up 0.83% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 360.5; the Oct 22, 2026 session ranged USD 360.65–367.93 on volume of 228,219 shares. Market capitalization is $9.72B, with a 52-week range of USD 236.73–396.23 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BIO.md
Key facts (BIO)
- Last four reported quarters (through Jun 30, 2026): revenue $2.59B, net income $222M (8.6% margin), free cash flow $353M (SEC filings).
- Valuation: P/E 43.7x (avg 10.9x at the last 1 fiscal year-ends), net cash $415M.
- 3 of 80 tracked superinvestors hold BIO (13F, Q2 2026): 0 new, 2 added, 1 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $136K; 1 not under a Rule 10b5-1 plan ($136K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 3.00 on a 1–5 scale) (3 analysts), mean target USD 335 (range 280–390).
- Total return with dividends: 1Y +7.3% vs S&P 500 +14.9%; 5Y -51.8% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 2.23, revenue estimate $650M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BIO)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.92B | $2.80B | $2.67B | $2.57B | $2.58B | $2.59B |
| Gross profit | $1.64B | $1.57B | $1.43B | $1.38B | $1.34B | — |
| Operating income | $500M | $483M | $338M | $269M | $47.2M | $53.1M |
| Net income | $4.25B | -$3.63B | -$637M | -$1.84B | $760M | $222M |
| EPS (diluted) | $140.83 | -$121.79 | -$21.82 | -$65.36 | $27.85 | — |
| Free cash flow | $536M | $81.6M | $218M | $290M | $375M | $353M |
| Gross margin | 56.1% | 55.9% | 53.4% | 53.7% | 51.9% | — |
| Operating margin | 17.1% | 17.2% | 12.6% | 10.5% | 1.8% | 2.1% |
| Net margin | 145.6% | -129.5% | -23.9% | -71.9% | 29.4% | 8.6% |
| Revenue growth | +14.8% | -4.1% | -4.7% | -3.9% | +0.7% | — |
| Cash + short-term investments | $870M | $1.79B | $1.61B | $1.66B | $1.54B | — |
| Total debt | $10.5M | $1.20B | $1.21B | $1.20B | $1.20B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BIO)
P/E 43.7x · P/S 3.8x · EV/Sales 3.6x · P/FCF 27.5x · P/B 1.4x · FCF yield 3.63% · Earnings yield 2.29% · Buyback yield (TTM) 1.37% · Net cash $415M · EV $9.30B
P/E at fiscal year-ends: Dec 2025 10.9x.
Superinvestors (SEC 13F-HR, Q2 2026) (BIO)
3 of 80 tracked investors hold BIO. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| John Rogers | Ariel Investments | 2.39% | $240M | Added +3.9% |
| First Pacific Advisors | 1.48% | $118M | Reduced -1.4% | |
| First Eagle Investment | First Eagle Investment Management | 1.28% | $765M | Added +0.1% |
Insider sales (SEC Form 4, open-market, last ~7 months) (BIO)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Engelhardt Eva Anette | EVP, President, CDG | 550 | $136K | 61.4% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (BIO)
Consensus Hold (mean 3.00 on a 1–5 scale), 3 analysts; mean target USD 335 (low 280, high 390).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | RBC Capital | Target raised | Outperform | $370 → $390 |
| 2026-08-05 | Citigroup | Target raised | Neutral | $300 → $330 |
| 2026-08-05 | RBC Capital | Target raised | Outperform | $320 → $370 |
| 2026-08-05 | Wells Fargo | Target raised | Equal-Weight | $310 → $330 |
Total return (dividends reinvested) (BIO)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +7.3% | -51.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +7.4% | -13.5% |
| Volatility (annualized) | 36.7% | 38.1% |
| Max drawdown | -28.9% (Oct 2025→May 2026) | -72.4% (Oct 2021→Jun 2025) |
BIO revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Clinical Diagnostics | $399.0M | 61.3% | +2.6% |
| Life Science | $252.0M | 38.7% | -4.1% |
| Total revenue | $651.0M | 100% | — |
BIO revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| UNITED STATES | $255.5M | 39.2% | -4.3% |
| Europe | $229.2M | 35.2% | +5.5% |
| Asia Pacific | $121.8M | 18.7% | -3.6% |
| Americas | $44.5M | 6.8% | +8.3% |
| Total revenue | $651.0M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
BIO suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Sartorius | “As of December 31, 2025, we owned 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius, of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries.” |
| Competitor | Thermo Fisher (TMO) | “Major competitors in this market include Becton Dickinson, Danaher, Merck KGaA, Qiagen N.V. and Thermo Fisher Scientific.” |
| Competitor | Merck (MRK) | “Major competitors in this market include Becton Dickinson, Danaher, Merck KGaA, Qiagen N.V. and Thermo Fisher Scientific.” |
| Competitor | Siemens | “Major competitors for our products in the Clinical Diagnostics segment include Abbott Laboratories, Becton Dickinson, bioMérieux, Danaher, DiaSorin, Werfen, QuidelOrtho, Roche, Siemens Healthineers, Thermo Fisher Scientific and Tosoh.” |
Quoted from the company's 10-K filed Feb 13, 2026.
Companies that name BIO in their SEC reports
| Relationship to BIO | Company | Filing | Sentence |
|---|---|---|---|
| partner | Insight Molecular Diagnostics Inc. (IMDX) | 10-K Mar 26, 2026 | “our dependency on our collaboration with Bio-Rad Laboratories, Inc. for the development and commercialization of products;” |
| customer | BIODESIX INC (BDSX) | 10-K Feb 26, 2026 | “For more information regarding this license and supply agreement and the permission granted to us by Bio-Rad with respect to such tests, please see "Business—Material Agreements—Agreements with Bio-Rad" filed with our Form S-1 on October 23, 2020 and "First Amendment to the Non-Exclusive License Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated May 24, 2021" filed with our Form 10-Q on August…” |
BIO company outlook (results filed Aug 4, 2026)
- “For the full-year 2026, the Company continues to expect non-GAAP, currency-neutral revenue to be in the range of a decline of approximately 3.0 percent to growth of approximately 0.5 percent, and an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent.”
- “Conference Call and Webcast Management will discuss the Company's second quarter 2026 results and financial outlook in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) on August 4, 2026.”
- “These forward-looking statements include, without limitation, statements we make regarding estimated future financial performance or results; remaining focused on the discipline we believe will drive growth, durable margin expansion, and long-term shareholder value creation; and for the full-year 2026: currently continuing to expect non-GAAP, currency-neutral revenue to be in th”
Quoted word-for-word from the SEC 8-K results press release.
BIO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $2.23 | $2.31 | -3.7% | $650.0M | 2 |
| Next quarter (ends Dec 2026) | $3.02 | $2.88 | +5.0% | $695.4M | 2 |
| Current fiscal year (ends Dec 2026) | $9.45 | $9.00 | +5.0% | $2.57B | 3 |
| Next fiscal year (ends Dec 2027) | $9.75 | $9.72 | +0.3% | $2.62B | 3 |
Key Statistics (as of October 23, 2026 at 09:23 UTC)
| Price | USD 363.5 |
|---|---|
| Change | ▲ 0.83% (up) |
| Previous Close | USD 360.5 |
| Open | USD 359.83 |
| Day Range | USD 360.65 – 367.93 |
| 52-Week Range | USD 236.73 – 396.23 |
| Volume | 228,219 shares |
| Market Cap | $9.72B |
| Exchange | NYQ |
Technical Analysis (BIO)
Nexqual's technical model rates BIO "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.78 (neutral) |
| vs SMA50 | Below (USD 372.82) |
| MACD | -3.7 (negative) |
Analyst Ratings (BIO)
Wall Street analysts rate BIO "Hold" based on 3 analysts, with a mean price target of USD 335 (range USD 280–390), per Nexqual as of October 23, 2026 at 09:23 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 335 |
| High Target | USD 390 |
| Low Target | USD 280 |
| Buy / Hold / Sell | 1 / 1 / 1 |
Earnings (BIO)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 2.23 |
| Revenue Estimate | $649.95M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.62 vs est 1.75 ▲ beat |
| 2026-03-31 | USD 1.89 vs est 1.99 ▼ miss |
| 2025-12-31 | USD 2.51 vs est 2.7 ▼ miss |
| 2025-09-30 | USD 2.26 vs est 1.93 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financials & Fundamentals (BIO)
| Total Revenue | $2.59B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -0.10% |
| Gross Margin | +52.04% |
| Operating Margin | +11.18% |
| Profit Margin | +8.59% |
| ROE | +3.11% |
| Debt / Equity | 0.19 |
| Current Ratio | 3.14 |
| Total Cash | $1.62B |
| Total Debt | $1.37B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $353.10M (13.6% of revenue) |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financial Health Score (BIO)
Nexqual rates Bio-Rad Laboratories, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:23 UTC.
| Growth | Mixed — Revenue +0.7% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 52%, operating 11% (last 12 months) |
| Balance Sheet | Strong — $1.62B cash and investments vs $1.20B debt (Jun 2026, SEC), net cash |
| Cash Flow | Solid — FCF $353M (last 4 quarters to Jun 2026, SEC), 14% margin |
| Efficiency | Weak — ROE 3%, ROA 1.7% |
Ownership (BIO)
| Insider Ownership | +16.41% |
|---|---|
| Institutional Ownership | +91.70% |
| Shares Outstanding | 21.68M |
| Float | 21.35M |
| Short % of Float | +7.44% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Leadership (BIO)
Bio-Rad Laboratories, Inc. is led by Norman D. Schwartz, Chairman & CEO, per Nexqual as of October 23, 2026 at 09:23 UTC.
| Chairman & CEO | Norman D. Schwartz |
|---|---|
| President & COO | Jonathan P. DiVincenzo |
| Executive VP & CFO | Roop K. Lakkaraju |
| Executive VP & President of Life Science Group | James J. Barry |
| Executive Vice President of Global Commercial Operations | Rajat Mehta |
Major Backers & Investors (BIO)
Notable institutional backers of Bio-Rad Laboratories, Inc. include First Eagle Investment Management, LLC, SmallCap World Fund Inc, Ariel Investments, LLC, according to Nexqual as of October 23, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Eagle Investment Management, LLC | 12.02% |
| SmallCap World Fund Inc | 4.07% |
| Ariel Investments, LLC | 3.77% |
| Earnest Partners LLC | 2.68% |
| Bank of America Corporation | 2.26% |
| Capital Group | 2.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.84% |
| Vanguard Group | 7.58% |
| Dimensional Fund Advisors | 4.36% |
| State Street | 2.64% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
From Bio-Rad Laboratories, Inc.'s Latest SEC 10-K Filing (filed 2026-02-13)
Key Strengths & Strategy (as disclosed to the SEC)
- We own over 2,100 U.S. and international patents and numerous trademarks.
Legal & Regulatory Risks (Item 1A, quoted)
- Our international operations expose us to additional costs and legal and regulatory risks, which could have a material adverse effect on our business, results of operations and financial condition.
- We are subject to substantial government regulation, and any changes in regulation or violations of regulations by us could adversely affect our business, prospects, results of operations or financial condition.
- Changes in tax laws or rates, changes in the interpretation of tax laws or changes in the jurisdictional mix of our earnings could adversely affect our financial position and results of operations.
- Environmental, health and safety regulations and enforcement proceedings may negatively impact our business, results of operations and financial condition.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PODD | Insulet Corporation | USD 148.12 | ▲ 4.38% |
| TXG | 10x Genomics, Inc. | USD 69.75 | ▼ 7.73% |
| BRKR | Bruker Corporation | USD 57.31 | ▼ 3.05% |
| GKOS | Glaukos Corporation | USD 176.69 | ▼ 0.09% |
| GMED | Globus Medical, Inc. | USD 81.66 | ▲ 3.79% |
| SNN | Smith & Nephew SNATS, Inc. | USD 30.88 | ▲ 5.64% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt